


**10<sup>TH</sup> ANNIVERSARY**



***10th Canadian CLL Research Meeting  
September 18 & 19, 2014  
Inn at the Forks, Winnipeg***



Keynote Speaker:

Dr. Michael Keating  
MD Anderson Cancer Centre  
Houston, TX

**Thursday, September 18, 2014**

- 7:30 am Breakfast
- 8:00 – 8:30 am Welcome & History of the Canadian CLL Meeting  
*James Johnston, CancerCare Manitoba, Winnipeg*
- 8:30 – 9:30 am Keynote Address  
**As the CLL World Turns**  
***Michael Keating***  
MD Anderson, Houston, TX

***Session I – Clinical Trials***  
***Chair: Carolyn Owen***

- 9:30-10:00 Ibrutinib in the treatment of CLL  
*Mohammed Farooqui, National Institutes of Health*
- 10:00-10:30 Idelalisib in the treatment of CLL  
*Jacqueline Barrientos, North Shore, Long Island Jewish School of Medicine*
- 10:30-10:45 COFFEE
- 10:45-11:15 Ruxolitinib in the treatment of elderly CLL  
*David Spaner, Sunnybrook Health Sciences Centre*
- 11:15-11:40 Ibrutinib resistance and HDAC inhibitor-mediated strategies to overcome them  
*Deepa Sampath, Ohio State University*
- 11:40-12:30 DEBATE: Is allogeneic transplantation still appropriate therapy for CLL in the era of novel agents?  
YES - *Cindy Toze, BC Cancer Agency, Vancouver*  
NO - *Chaim Shustik, McGill University, Montreal*
- 12:30-1:15 LUNCH

**Thursday, September 19, 2014**

***Session II – Clinical Characteristics of CLL  
Chair: Cindy Toze***

- |           |  |
|-----------|--|
| 1:15-1:45 | Monoclonal B cell lymphocytosis in healthy blood donors<br><i>Gerald Marti, National Institutes of Health</i>      |
| 1:45-2:15 | Lymphocyte count cut-offs in MBL/CLL<br><i>Timothy Call, Mayo Clinic</i>   |
| 2:15-2:40 | Familial CLL<br><i>Sara Beiggi, Mayo Clinic</i>  |
| 2:40-2:55 | COFFEE   |
| 2:55-3:20 | Epidemiological studies on statins in CLL and Lymphomas<br><i>Xibiao Ye, Manitoba Institute of Cell Biology</i>    |
| 3:20-3:45 | Hypercholesterolemia in CLL and response to statin therapy<br><i>Signy Chow, Sunnybrook Health Sciences Centre</i> |
| 3:45-4:10 | Biclonal CLL<br><i>James Johnston, Cancer Care Manitoba, Winnipeg</i>  |
| 4:10-4:25 | CLL Patient Advocacy Group Update<br><i>Rebecca Drotos</i>   |
| 4:25-5:00 | Intellectual History of CLL – Role of Michael Keating<br><i>Gerald Marti, National Institutes of Health</i>        |
| 5:00-7:00 | POSTERS  |
| 7:15      | DINNER   |

**Friday, September 19, 2014**

7:30 am

Breakfast

***Session III – Basic Research in CLL  
Chair: David Spaner***

8:15-8:45

Targeting CD160 in CLL  
*Sam Agrawal, St Bartholomew's Hospital, London UK*

8:45-9:15

Mechanisms of marrow toxicity from fludarabine  
*Brent Zanke, University of Ottawa*

9:15-9:45

Cytokines in CLL  
*Barbara Sherry, Hofstra North Shore, Long Island Jewish School of Medicine*

9:45-10:15

Antibody resistance in CLL  
*Clive Zent, University of Rochester, Minnesota*

10:15-10:30

COFFEE

10:30-10:55

AKT inhibition in CLL  
*Wei Ding, Mayo Clinic*

10:55-11:20

Signals controlling CLL migration and adhesion to stromal cells  
*Aaron Marshall, University of Manitoba*

11:20-11:45

NAMPT-inhibition is effective treatment in resistant CLL  
*Iris Gehrke, CancerCare Manitoba, Winnipeg*

11:45-12:10

Epigenetic programming in CLL  
*Chris Oakes, Heidelberg, Germany*

12:10-1:00

LUNCH

1:00-1:25

Prognostic value of telomere length in CLL  
*Lin Yang, Cancer Care Manitoba, Winnipeg*

1:25-1:50

Advanced Diagnostics Research Lab (ADRL)  
*John DeCoteau, Saskatchewan Cancer Agency*

1:50-2:15

DNA repair in CLL  
*Lilian Amrein, McGill University, Montreal*

2:15-2:40

Targeting lysosomes in CLL  
*Rebecca Dielschneider, CancerCare Manitoba, Winnipeg*

2:40-2:45

CLOSING WORDS